Pitolisant
This page is a reference summary of published evidence and regulatory documents. It is not a substitute for individual medical advice, and it is not a recommendation to take or avoid any medicine.
Medically reviewed by Dr. Sofia Lindqvist, · Last reviewed 11 August 2026
Pitolisant, sold as Wakix, is a histamine H3 receptor antagonist and inverse agonist approved by the FDA in 2019. It stands out for two reasons: it works through a genuinely different mechanism from every other drug in this section, and it is not a controlled substance.
On this page
How it works
H3
receptor target
2019
year of FDA approval
None
DEA schedule
Yes
treats cataplexy
Histamine is one of the brain’s principal wake-promoting neurotransmitters. H3 receptors act as autoreceptors: they sit on histamine neurons and suppress further histamine release when activated.
Pitolisant blocks those receptors and acts as an inverse agonist, which removes the brake and increases histamine release. Wakefulness is enhanced through the histaminergic system rather than the dopaminergic one.
H3 autoreceptor
normally suppresses release
Blocked + inverted
brake removed
Histamine ↑
hypothalamic tuberomammillary neurons
Daytime wakefulness
Pitolisant works by releasing a brake rather than pressing an accelerator — the reason it sits outside the controlled-substance schedules.
This matters clinically because it is the only mechanism in the class that does not work primarily through catecholamines. Histamine activity during the day is relevant in narcolepsy, and promoting it addresses the deficit from a different direction.
Approved uses
Pitolisant is FDA approved for the treatment of cataplexy or excessive daytime sleepiness in adults and paediatric patients with narcolepsy.
| Pitolisant | Modafinil / armodafinil | Solriamfetol | |
|---|---|---|---|
| Daytime sleepiness | Yes | Yes | Yes |
| Cataplexy | Yes | No | No |
| Paediatric indication | Yes | No | No |
| Controlled substance | No | Schedule IV | Schedule IV |
Not a controlled substance
Pitolisant is not scheduled by the DEA. Because it does not act on dopamine transporters and does not produce the reinforcing effects associated with stimulants, it lacks the abuse liability that places modafinil in Schedule IV and amphetamines in Schedule II. For patients with a history of substance use disorder, or where controlled-substance prescribing is a practical obstacle, that is a meaningful advantage.
Evidence
Efficacy was evaluated in two multicentre, randomised, double-blind, placebo-controlled studies in 261 patients with narcolepsy, with and without cataplexy. Both demonstrated statistically significant improvement in Epworth Sleepiness Scale scores.
Cardiac considerations and interactions
Discuss antidepressants with the prescriber
Pitolisant affects cardiac conduction, and there is a recognised interaction concern with antidepressants. Clinicians have noted that concurrent antidepressant use may facilitate arrhythmias, though this has not been well studied. Some prescribers monitor with ECG; practice varies. Anyone taking an antidepressant alongside pitolisant should have the combination reviewed.
Is pitolisant a controlled substance?
No. It is not scheduled by the DEA, because it does not act on dopamine transporters and does not produce the reinforcing effects associated with stimulants.
Does pitolisant treat cataplexy?
Yes. It is approved for cataplexy as well as excessive daytime sleepiness in narcolepsy, which sets it apart from modafinil, armodafinil and solriamfetol.
Can it be taken with an antidepressant?
It needs review by the prescriber. Pitolisant affects cardiac conduction, and clinicians have noted that concurrent antidepressant use may facilitate arrhythmias, though this has not been well studied.